Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 110

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 2
Chunk 110
---
190

			Unallocated internal costs

			261,662

			288,728

			(27,066
			)

			Total unallocated internal costs

			262,852

			288,728

			(25,876
			)

			Total research and development costs

			484,306

			1,176,337

			(692,031
			)

			●

			Research and development (R&D) expenses decreased by $0.7 million to $0.5 million for the three months ended March 31, 2025 compared to $1.2 million for the same period last year primarily due to decreased external research expenses related to EB05 (paridiprubart) in the comparative period, offset partially by an increase in EB06 related expense as we prepare for the Phase 2 clinical study. Our R&D expenses consist primarily of employee-related expenses, including salaries, benefits, taxes, travel, and share-based compensation expense for personnel in R&D functions; expenses related to process development and production of product candidates paid to contract manufacturing organizations, including the cost of acquiring, developing, and manufacturing research material; costs associated with clinical activities, including expenses for contract research organizations; and clinical trials and activities related to regulatory filings for our product candidates, including regulatory consultants.

			●

			General and administrative (G&A) expenses increased by $0.2 million to $1.2 million for the three months ended March 31, 2025 compared to $1.0 million for the same period last year primarily due to an increase in salaries and related costs, partially offset by a decrease in noncash share-based compensation and professional service fees. Our G&A expenses consist primarily of salaries and related costs for our employees in administrative, executive and finance functions. G&A expenses also include professional fees for legal, accounting, audit, tax and consulting services, insurance, office, and travel expenses.

Total other income decreased by $311,000 to $49,000 for the three months ended March 31, 2025 compared to $360,000 for the same period last year and was composed of the following:

			●
			
			Grant income decreased by $0.2 million to $0.1 million for the three months ended March 31, 2025 compared to $0.3 million for the three months ended March 31, 202